2016 Annual Meeting

American Association of Neuropathologists

Room CC 608-609, March 12 2016, 7:00pm to 10:00pm

Description

American Association of Neuropathologists

Neuropathology Companion Society Meeting
A Tribute to Dr. F. Stephen Vogel

Saturday, March 12, 2016
7:00 PM 10:00 PM
CC 608 609

Moderators: Gregory Fuller, MD, PhD, MD Anderson Cancer Center, Houston, TX
Tarik Tihan, MD, PhD, University of California, San Francisco, CA

Course Description:
Understanding of the underlying molecular drivers of malignant human brain tumor genesis and progression has increased dramatically and exponentially over the past 10 years. This expanded knowledge has led to the implementation of clinically-critical molecular signature determination for the major group of pediatric brain tumors (primitive neuroectodermal, or embryonal, tumors, including medulloblastoma) as well as the major group of adult brain tumors (the diffuse gliomas, including glioblastoma). The degree of maturity that the field has reached lead to an international colloquium in Haarlem, The Netherlands, in April, 2014, in which the principles of a major revision of the World Health Organization Classification of Tumours of the Central Nervous System were debated and the conclusions codified (1). Based on this foundation, a new, fully revised, Brain Tumor Classification will be released in March, 2016, which will include, for the first time, the incorporation of clinically-critical molecular signature elements into the definition and diagnosis of the major classes of malignant brain tumors, including the most common childhood brain malignancy, medulloblastoma, and the most common adult brain tumor, glioblastoma, among others. There is therefore an urgent need to educate pathologists at all levels of career, from trainees to seasoned private practicioners and professors, on the new BrainTumor Diagnosis and Classification system and how to implement it in the real world of clinical practice. This program will directly address this pressing need.

Upon completion of this educational activity, participants should be able to:

  1. Understand the major clinically-relevant molecular alterations that underlie human brain malignancy tumorigenesis and that have strong predictive power with regard to response to therapy and prognosis.
  2. Implement the determination and incorporation of clinically-critical molecular signatures into the diagnosis of individual patient tumors using immunostain surrogate markers and other techniques that are commonly available in the diagnostic pathology laboratory.
  3. Learn how molecular signature determination can facilitate accurate diagnosis in the face of problematic tumors and in tumor histologic mimicry situations, and will be able to incorporate the new changes in brain tumor diagnosis into their daily clinical practice.

Agenda

7:00 PM

Opening Remarks: A Tribute to Dr. F. Stephen Vogel
Gregory Fuller, MD, PhD, MD Anderson Cancer Center, Houston, TX

7:10 PM

Reflections on a Career in Surgical Neuropathology
Peter Burger, MD, The Johns Hopkins Hospital, Baltimore, MD

8:00 PM

What Do I Do with this Low Grade Glioma?
Craig Horbinski, MD, PhD, University of Kentucky, Lexington, KY

8:30 PM

If This is Not Glioblastoma, Then What is It?
Murat Gokden, MD, University of Arkansas for Medical Sciences, Little Rock, AR

9:00 PM

How Do I Report this Embryonal Tumor?
Maria Martinez-Lage Alvarez, MD, Hospital of University of Pennsylvania, Philadelphia, PA

Meetings

home-circle-inset-1
view more